[关键词]
[摘要]
甲状腺相关眼病(TAO)是一种罕见的器官特异性自身免疫性疾病，发病机制尚未明确。目前治疗仍主要依赖糖皮质激素和传统免疫抑制剂，部分患者对这些药物反应不佳，同时存在治疗相关不良反应，因此迫切需要治疗TAO的新型药物。近年来，随着对TAO发病机制研究的不断深入，针对特定靶点研发的生物制剂层出不穷，其中靶向胰岛素样生长因子-Ⅰ受体(IGF-IR)的替妥木单抗已被美国食品和药物管理局批准用于治疗TAO，还有多种生物制剂处于临床试验阶段。本文通过总结针对IGF-IR、新生儿Fc受体(FcRn)、促甲状腺激素受体(TSHR)、B细胞、细胞因子等的生物制剂在TAO中的临床研究现状，分析其对临床治疗及未来研究趋势的影响，为TAO临床防治和研究提供最新参考。
[Key word]
[Abstract]
Thyroid-associated ophthalmopathy(TAO)is a rare organ-specific autoimmune disease with an unclear pathogenesis. At present, the treatment still relies mainly on glucocorticoids and traditional immunosuppressants. However, some patients respond poorly to these drugs and experience treatment-related adverse reactions, highlighting the urgent need for novel drugs for TAO treatment. In recent years, with the deepening of research on the pathogenesis of TAO, a multitude of biologics targeting specific targets have emerged. Among them, teprotumumab, which targets the insulin-like growth factor-I receptor(IGF-IR), has been approved by the Food and Drug Administration for the treatment of TAO, and several other biologics are currently in clinical trials. This review provides the latest reference for the clinical prevention, treatment, and research of TAO by summarizing the current clinical research status of biologics targeting IGF-IR, neonatal Fc receptor(FcRn), thyroid-stimulating hormone receptor(TSHR), B cells, cytokines, and other biological agents in TAO and analyzing their impact on clinical treatment and future research trends.
[中图分类号]
[基金项目]
河南省中医药传承与创新人才工程(仲景工程)中医药拔尖人才项目(No.CZ0237-02); 河南省中医药科学研究专项课题(No.20-21ZY1016); 河南中医药大学2022年度研究生科研创新项目(No.2022KYCX043)
